GlaxoSmithKline

Your Partner in Respiratory Care is pleased to support AllerGen’s third annual conference, Innovation from Cell to Society

GlaxoSmithKline (GSK) is a research-based pharmaceutical company devoted to discovering and developing new and innovative medicines, vaccines and healthcare products for Canadians and people around the world. Our key products target five major disease areas — respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. GSK is also a leader in the important area of vaccines and we are developing new treatments for cancer.

www.gsk.ca

Do more, feel better, live longer
Proud Platinum Sponsor of the AllerGen NCE Inc. Third Annual Research Conference.
Welcome from the Board Chair and Scientific Director

On behalf of the AllerGen Board of Directors, Research Leaders, Administrative Centre and our generous conference sponsors, we welcome you to our third Annual Research Conference, Innovation from Cell to Society. This year our focus is on a pressing issue of great concern to Canadians and to people around the world: “Allergy and the Environment.”

Since its launch in 2004, AllerGen has enabled more than 500 researchers, trainees, business leaders, industry entrepreneurs, policy makers, healthcare providers and patient advocates to form national and international communities of investigators and stakeholders who are collectively focused on reducing the impact of allergy, asthma and anaphylaxis. These partnerships, supplemented by the recent establishment of linkages between AllerGen and a range of international research organizations and networks, underpin the Network’s ability to undertake research that can be translated into economic and social benefits for Canadians, and position Canada as a leader on the world stage in translational research addressing allergic and related immune diseases.

This conference programme provides opportunities to learn more about state-of-the-art research in allergy and asthma across multiple disciplines. It also provides a forum in which we can strengthen our professional and personal ties, and identify new opportunities for collaboration and partnership.

We hope that this conference will inspire and encourage you to move forward with novel ideas and build new scientific and community relationships that will lead to an improved quality of life for children and adults suffering from allergic and related immune diseases.

Mot de bienvenue du président du conseil d’administration et du directeur scientifique

Au nom du conseil d’administration d’AllerGen, de nos chercheurs de pointe, de nos administrateurs et de nos généreux commanditaires, il nous fait le plus grand plaisir de vous accueillir à la troisième conférence de recherche annuelle du Réseau, Innovation de la cellule à la société. Cette année, notre thème porte sur un enjeu qui préoccupe grandement les Canadiens et les citoyens de tous les pays : les allergies et l’environnement.

Depuis son inauguration en 2004, AllerGen a aidé à plus de 500 chercheurs, scientifiques en formation, sommités du secteur privé, partenaires industriels, décideurs et défenseurs des droits des patients à former, à l’échelle nationale et internationale, des partenariats de recherche et d’intervention qui travaillent ensemble à réduire l’impact des allergies, de l’asthme et de l’anaphylaxie. Étayés par de nouveaux liens établis avec d’importants réseaux et organismes de recherche à l’échelle internationale, ces partenariats viennent renforcer notre capacité de réaliser des projets de recherche qui auront une incidence positive marquée sur l’économie et la qualité de vie de tous les Canadiens, en plus de positionner le Canada parmi les chefs de file mondiaux de la recherche appliquée dans le domaine des allergies allergiques et immunitaires.

Le programme de la conférence vous invite à approfondir votre connaissance de la recherche multidisciplinaire de pointe portant sur l’asthme et les affections allergiques, en plus d’offrir de nombreuses occasions de réseautage professionnel et personnel qui mèneront, nous l’espérons, à de nouvelles initiatives de collaboration et de partenariat.

Nous souhaitons que cette conférence servira de source d’inspiration, qu’elle vous encouragera à aller de l’avant avec de nouvelles idées et à établir de nouveaux partenariats scientifiques et communautaires qui amélioreront la qualité de vie des enfants et des adultes souffrant d’asthme et d’affections allergiques et immunitaires.
Welcome to beautiful Banff, Alberta, and to AllerGen’s third annual scientific conference, Innovation from Cell to Society.

Over the next few days, you will be discussing the latest scientific advances in the field of allergic and immune diseases. This is also a time for you to share your experiences and ideas to improve the quality of life for the tens of thousands of Canadians who suffer from these conditions.

AllerGen has mobilized researchers, clinicians and partners from many sectors, all of whom are focused on a common goal: improving the health of Canadians and the quality of care available to them. Your Network’s efforts to acquire knowledge, commercialize its discoveries and train highly-qualified knowledge workers are enhancing Canada’s health and well-being.

AllerGen’s successes and the impact of its research are examples of the advantages gained when business, academic and public sectors work together. The Government of Canada is committed to allowing such partnerships to flourish. Through our Science and Technology Strategy, we are fostering an environment where ideas and research are given the leverage needed for meaningful, wide-reaching benefits. Indeed, since Budget 2007, this Government has announced well over $200 million in new funding initiatives to expand and enhance the Networks of Centres of Excellence program alone. These and other recent and ongoing initiatives will allow Canada to take better advantage of the enviable research capacity we have built over the years. Investing in science and technology now will lead to a stronger, healthier, more sustainable Canada in the future.

On behalf of the Government of Canada, I thank you for your ongoing dedication to reducing the suffering caused by allergic disease while helping to place Canada at the forefront of the global knowledge economy. I wish you a productive and enjoyable conference.

The Honourable Jim Prentice
Minister of Industry

Message from the Honourable Jim Prentice, Minister of Industry

About AllerGen

AllerGen NCE Inc. is dedicated to improving the quality of life for people suffering from allergic and related immune diseases.

Our Vision
To create an enduring network of allergy and immune disease experts whose discovery and development efforts contribute to reducing the impact of allergic and related immune diseases nationally and globally.

Our Mission
To catalyze and support discovery, development, networking, capacity building, commercialization and knowledge translation that contribute to reducing the morbidity, mortality and socio-economic burden of allergic and related immune diseases.

Our Strategic Goals
1. Catalyze and support innovative research that contributes to the discovery of the causes of, and ways to prevent, control or eliminate allergic and related immune diseases.
2. Create new opportunities for the training of highly qualified entrepreneurial personnel in allergy research, patient care, innovation and the health system, and advance professional and lay knowledge about allergic and related immune diseases.
3. Catalyze and facilitate the development of new research platforms, tools, processes, products and services arising from discoveries, and promote their commercialization, their use and their influence on public policy.
4. Develop and maintain networking and partnership arrangements that enable knowledge and technology exchange and exploitation (KTEE).
5. Provide responsible, cost effective and accountable management, administration and support to all aspects of AllerGen’s activities.

At McMaster, we know complex issues require integrated solutions. Digging deep is second nature to us. Our innovative and multi-disciplinary approach to research has earned us international acclaim. But more than that, it’s helped to save lives and contribute to the nation’s social and economic well-being.

It is indeed fitting that McMaster University is home to AllerGen NCE Inc., a dynamic centre of excellence that shares our philosophy and approach to research.

mcmaster.ca/research

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. Novartis Pharmaceuticals Canada conducts hundreds of clinical trials across the country seeking new treatments for cardiovascular disease, diabetes, cancer, organ transplantation and ophthalmic diseases. In 2006, the Company invested over $69 million in research and development. Novartis Pharmaceuticals Canada Inc. employs approximately 850 people in Canada and its headquarters are located in Dorval, Quebec.

Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd., Dorval, QC H9S 1A9
(514) 631-6775 www.novartis.ca
Bienvenue dans le cadre enchanteur de Banff (Alberta) et au troisième congrès scientifique annuel d’AllerGen ayant pour thème L’innovation de la cellule à la société.

Au cours des prochains jours, vous traiterez des plus récents progrès scientifiques dans le domaine des allergies et des déficiences immunitaires. C’est également une occasion pour vous de partager votre expérience et d’échanger des idées pour améliorer la qualité de vie des dizaines de milliers de Canadiens qui souffrent de ces affections.

AllerGen a réussi à mobiliser des chercheurs, cliniciens et partenaires de plusieurs disciplines envers un objectif commun : améliorer la santé des Canadiens et la qualité des soins qui leur sont disponibles. Les efforts déployés par votre Réseau pour acquérir le savoir, commercialiser ses découvertes et former la main d’œuvre hautement spécialisée, contribuent à améliorer la santé et le mieux-être des Canadiens.

Les succès d’AllerGen et les incidences de ses travaux de recherche sont des exemples des avantages qui résultent de la concertation des secteurs public, universitaire et commercial. Le gouvernement du Canada, qui a accordé aux sciences et la technologie maintenant assurera un Canada en meilleure santé, plus fort et plus viable dans l’avenir.

Au nom du gouvernement du Canada, je tiens à vous remercier pour votre travail inlassable à réduire la souffrance causée par les allergies tout en contribuant à placer le Canada au premier rang de l’économie mondiale du savoir. Je vous souhaite un excellent et fructueux congrès.

L’honorable Jim Prentice
Ministre de l’Industrie
Conference Information

The registration desk is located outside the Wildrose Ballroom on Level 6, South Wing, of the Rimrock Resort.

The Registration/Information Desk will be staffed at the following times:
- Sunday, February 10: 1:00 pm to 6:00 pm
- Monday, February 11: 7:30 am to 4:00 pm
- Tuesday, February 12: 7:30 am to Noon

Admission to conference events is by CONFERENCE NAME BADGE ONLY. Registrations are non-transferable and sharing of registration is not permitted.

Full registration includes:
- Sunday Welcome Reception; breakfasts, breaks, lunches, Reception and Gala Dinner at the Rimrock;
- All scientific sessions; and
- Conference handouts.

One-day registration includes:
- Scientific sessions on specific day;
- Breakfasts, breaks and lunches; and
- Conference handouts.

Conference Chair
Diana Royce
Managing Director and COO
AllerGen NCE Inc.

Organizing Committee
Judah A. Denburg
Scientific Director and CEO
AllerGen NCE Inc.
Frank Viti
AllerGen Board of Directors
Louis-Philippe Boulet
AllerGen Research Management Committee
Jeffrey Brook
AllerGen Research Management Committee
Timothy Caulfield
AllerGen Research Management Committee
Peter Paré
AllerGen Research Leader

Charles Frankish
AllerGen Not-for-Profit Partner
Paolo Renzi
AllerGen Private Sector Partner
Jeremy Beach
AllerGen Investigator
Jean Marshall
AllerGen Investigator
Irvin Mayers
AllerGen Investigator
P.J. Subbarao
AllerGen Investigator
Susan Waserman
AllerGen Investigator
Anne Ellis
Chair, AllerGen Students and New Professionals Network
Samantha Simpkin
Office Manager
AllerGen NCE Inc.

Research Symposiums cont’d

Proposed clinical studies
Dr. Mark Fitzgerald, AllerGen Investigator
Director, Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute

New initiatives: Vaccine trial development
Mark Larché, PhD, AllerGen Investigator
Professor, McMaster University

Pharmacogenetic platform
Scott Tebdutt, PhD, AllerGen Investigator
Assistant Professor, University of British Columbia

3:30-3:45 pm Break
Wildrose Foyer, Level 6, South Wing

3:45-4:30 pm Research Symposium
Wildrose BC, Level 6, South Wing

Occupational asthma
Moderator: Dr. Nicola Cherry, AllerGen Investigator
Professor, University of Alberta

Work-related asthma: An evaluation of two surveillance programs
Mieke Koehoorn, PhD, AllerGen Investigator
Associate Professor, University of British Columbia
Niki Garzia, AllerGen Trainee
University of British Columbia

Surveillance and spin-off studies
Dr. Nicola Cherry, AllerGen Investigator
Professor, University of Alberta
Dr. Jeremy Beach, AllerGen Investigator
Associate Professor, University of Alberta
Igor Burstyn, PhD, AllerGen Investigator
Associate Professor, University of Alberta
Yuxin Liu, AllerGen Trainee
University of Alberta

4:30-5:30 pm Keynote Speaker
Wildrose BC, Level 6, South Wing

“A Journalist’s Perspective” Science As I’ve Seen It
Bob McDonald
Host of CBC Radio’s Quirks and Quarks

5:30 pm Closing Remarks
Wildrose BC, Level 6, South Wing
Dr. Judah Denburg
Scientific Director and COO, AllerGen NCE Inc.

5:30-6:30 pm Poster Session and Final Adjudication
Wildrose BC and Foyer, Level 6, South Wing

6:30-10:00 pm Reception & Gala Dinner, Trainee Awards
Wildrose A and Foyer, Level 6, South Wing

Mark your calendars!

Fourth Annual Research Conference
INNOVATION FROM CELL TO SOCIETY
February 15-17, 2009 • Ottawa, Ontario
Tuesday, February 12

7:30-8:55 am Breakfast Buffet Wildrose A, Level 6, South Wing

8:55-9:00 am Overview of Day’s Program Wildrose BC, Level 6, South Wing Dr. Judah Denburg, Scientific Director and CEO, AllerGen NCE Inc.

9:00-10:30 am Research Symposium Wildrose BC, Level 6, South Wing

The immunology of allergy and asthma: CanGoFar and Biomarkers
Moderator: Dr. Louis-Philippe Boulé, AllerGen Investigator, and Professor, School of Environmental Health, University of British Columbia

Canadian Group on Food and Allergy Research (CanGoFar) overview
Jean Marshall, PhD, AllerGen Investigator, Professor, Dalhousie University

CanGoFar data
Dr. Manel Jordana, AllerGen Investigator, Associate Professor, McMaster University

Non-invasive assessment of atopic diseases: Metabolomic profiling of urine using Nuclear Magnetic Resonance (NMR)
Dr. Darryl Adamko, AllerGen Investigator, Associate Professor, University of Alberta

Regulation of CRTh2, a receptor involved in allergic inflammation
Lisa Cameron, PhD, AllerGen Investigator, Assistant Professor, University of Alberta

10:30-11:00 am Break Wildrose Foyer Level 6, South Wing

11:00 am-12:30 pm Research Symposium Wildrose BC, Level 6, South Wing

Health policy issues in allergy, anaphylaxis and asthma
Moderators: Dr. Allan Becker, Programme Leader, Public Health, Ethics, Policy and Society, and Professor, University of Manitoba
Susan Elliott, PhD, Programme Leader, Public Health, Ethics, Policy and Society, and Dean of Social Sciences and Professor, McMaster University

Food labelling and policies for the allergic consumer
Dr. Ann Clarke, AllerGen Investigator, Associate Professor, McGill University Health Centre

Health professionals: Delivering asthma education and support to children with asthma
Miriam Stewart, PhD, AllerGen Investigator, Professor, University of Alberta

Perinatal stress and immigration: Potential impact on allergic disease development in offspring
Dr. Claudia Soares, AllerGen Investigator, Associate Professor, McMaster University

12:30-2:00 pm Luncheon and Poster Viewing Wildrose ABC and Foyer, Level 6, South Wing

2:00-3:30 pm Research Symposium Wildrose BC, Level 6, South Wing

Clinical Investigator Collaborative
Moderator: Dr. Paul O’Byrne, Programme Leader, Diagnostics and Therapeutics, Chair, Department of Medicine, McMaster University

Ongoing clinical studies
Dr. Louis-Philippe Boulé, AllerGen Investigator, Professor, University of Alberta

Completed clinical studies
Gail Gauvreau, PhD, AllerGen Investigator, Assistant Professor, McMaster University

Conference Program

Sunday, February 10

3:30-4:30 pm Environmental Exposure Workshop: Public Plenary Session Hawthorne, Level 6, South Wing
The Cup is half full: Strategies for the selective collection, saving and measurement of estimated exposures in birth cohort studies to test current and future central hypotheses on the origins of allergy and asthma
Dr. Diane Gold, Associate Professor, Harvard Medical School, Brigham and Women’s Hospital, Channing Laboratory, Boston, Massachusetts

5:00-6:00 pm Opening Ceremonies Wildrose BC, Level 6, South Wing
Welcome and Introductions
Chaviva Holek, PhD, Vice-Chair, Board of Directors, AllerGen NCE Inc.

Messages from Invited Guests
Dr. Rose Goldstein, Vice-President (Research), University of Calgary
Jacques Magnan, PhD, Interim President and CEO, Alberta Heritage Foundation for Medical Research

7:00-8:00 pm Welcome Reception for all Conference Delegates Wildrose A, Level 6, South Wing

AllerGen: Back to the future
Dr. Judah Denburg, Scientific Director and CEO, AllerGen NCE Inc.

Monday, February 11

7:30-9:00 am Breakfast Buffet Wildrose A, Level 6, South Wing

8:55-9:00 am Welcome Wildrose BC, Level 6, South Wing Dr. Judah Denburg, Scientific Director and CEO, AllerGen NCE Inc.

9:00-10:30 am Research Symposium & Panel Discussion Wildrose BC, Level 6, South Wing
Assessment of environmental exposure related to asthma and allergy
Moderators: Dr. Jeffrey Brook, PhD, AllerGen Research Management Committee (RMG) and Senior Scientist, Air Quality Research Division, Environment Canada
Michael Brauer, ScD, AllerGen Investigator, and Professor, School of Environmental Health, University of British Columbia

Tuesday, February 12

7:30-8:55 am Breakfast Buffet Wildrose A, Level 6, South Wing

8:55-9:00 am Overview of Day’s Program Wildrose BC, Level 6, South Wing Dr. Judah Denburg, Scientific Director and CEO, AllerGen NCE Inc.

9:00-10:30 am Research Symposium Wildrose BC, Level 6, South Wing

The immunology of allergy and asthma: CanGoFar and Biomarkers
Moderator: Dr. Allan Becker, Programme Leader, Public Health, Ethics, Policy and Society, and Professor, University of Manitoba

Canadian Group on Food and Allergy Research (CanGoFar) overview
Jean Marshall, PhD, AllerGen Investigator, Professor, Dalhousie University

CanGoFar data
Dr. Manel Jordana, AllerGen Investigator, Associate Professor, McMaster University

Non-invasive assessment of atopic diseases: Metabolomic profiling of urine using Nuclear Magnetic Resonance (NMR)
Dr. Darryl Adamko, AllerGen Investigator, Associate Professor, University of Alberta

Regulation of CRTh2, a receptor involved in allergic inflammation
Lisa Cameron, PhD, AllerGen Investigator, Assistant Professor, University of Alberta

10:30-11:00 am Break Wildrose Foyer Level 6, South Wing

11:00 am-12:30 pm Research Symposium Wildrose BC, Level 6, South Wing

Health policy issues in allergy, anaphylaxis and asthma
Moderators: Dr. Allan Becker, Programme Leader, Public Health, Ethics, Policy and Society, and Professor, University of Manitoba
Susan Elliott, PhD, Programme Leader, Public Health, Ethics, Policy and Society, and Dean of Social Sciences and Professor, McMaster University

Food labelling and policies for the allergic consumer
Dr. Ann Clarke, AllerGen Investigator, Associate Professor, McGill University Health Centre

Health professionals: Delivering asthma education and support to children with asthma
Miriam Stewart, PhD, AllerGen Investigator, Professor, University of Alberta

Perinatal stress and immigration: Potential impact on allergic disease development in offspring
Dr. Claudia Soares, AllerGen Investigator, Associate Professor, McMaster University

12:30-2:00 pm Luncheon and Poster Viewing Wildrose ABC and Foyer, Level 6, South Wing

2:00-3:30 pm Research Symposium Wildrose BC, Level 6, South Wing

Clinical Investigator Collaborative
Moderator: Dr. Paul O’Byrne, Programme Leader, Diagnostics and Therapeutics, Chair, Department of Medicine, McMaster University

Ongoing clinical studies
Dr. Louis-Philippe Boulé, AllerGen Investigator, Professor, University of Alberta

Completed clinical studies
Gail Gauvreau, PhD, AllerGen Investigator, Assistant Professor, McMaster University
Research Symposium & Panel Discussion cont’d

Keynote Speaker

New findings, concepts and hypotheses regarding air pollution, asthma and allergy

Bert Brunekreef, PhD
Professor, Environmental Epidemiology
Director, Institute for Risk Assessment Sciences
Utrecht University, the Netherlands

Environmental exposure assessments: A report from AllerGen’s environment exposures workshop

Jeffrey Brook, PhD, AllerGen Investigator
Senior Scientist, Air Quality Research Division, Environment Canada

Panel Discussion and Q&A: What environmental exposures are most important to quantify and how much can we realistically know?

Moderator: Frances Silverman, PhD, AllerGen Investigator
Director of Research, Gage Occupational and Environmental Health Unit, and Associate Professor, University of Toronto

Panelists (including Dr. Brook, Bruer and Brunekreef):

Dr. Diane Gold
Associate Professor, Harvard Medical School

Dr. Stephanie Landon
Senior Investigator, National Institute of Environmental Health Sciences

James Scott, PhD, AllerGen Investigator
Assistant Professor, University of Toronto

Dr. Tim Takaro, AllerGen Investigator
Associate Professor, Simon Fraser University

10:30-11:00 am
Break
Wildrose Foyer, Level 6, South Wing

11:00 am-12:30 pm
Research Symposium
Wildrose BC, Level 6, South Wing

Birth cohorts in the study of allergy and asthma: Past, present and future

Moderator: Dr. Peter Paté, Programme Leader, Gene-Environment Interactions

Introduction: Growing up with asthma
Dr. Malcolm Sears, Programme Leader, Gene-Environment Interactions
Research Director, Firestone Institute for Respiratory Health
Professor, McMaster University

Collaboration among European birth cohorts in the GA2LEN network of excellence
Dr. Susanne Lau
Assistant Professor, Charité - Medical University Berlin, Germany

Department of Pediatric Pneumology and Immunology, Campus Virchow Klinikum

Health consequences and environmental burden of allergen exposure: Results of the German birth cohort, LISA
Joachim Heinrich, PhD
Head, Environmental Epidemiology, GSF National Research Center for Environment and Health, Institute for Epidemiology

12:30-2:00 pm
Luncheon and Poster Viewing
Wildrose ABC and Foyer, Level 6, South Wing

2:00-3:30 pm
Research Symposium and Panel Discussion
Wildrose BC, Level 6, South Wing

CHILD is born: Nature and nurture

Moderator: Dr. Malcolm Sears, Programme Leader, Gene-Environment Interactions

Objective assessment of lung function and inflammation in infants: Is it possible?
Dr. Padmaja Subbarao, AllerGen Investigator
Assistant Professor, Hospital for Sick Children

Gender differences in the presentation of atopy and asthma: Implications for longitudinal birth cohort studies
Dr. Prush Mandhan, AllerGen Investigator
Assistant Professor, University of Alberta

Mini-CCHILD into CHILD: Lessons learned from piloting the CHILD study in B.C.
Dr. Stuart Turvey, AllerGen Investigator
Assistant Professor, University of British Columbia

SAGE (the Manitoba cohort) to CHILD: Looking backward – moving forward!
Dr. Ganesh Sinivasan, AllerGen Investigator
Assistant Professor, University of Manitoba

Panel Discussion and Q&A: Lessons for CHILD

Panelists:

Dr. Rick Hegele
Professor, University of British Columbia

Dr. Bruce Ritchie
Assistant Professor, University of Alberta

Krisp Van Steen, PhD
Assistant professor, Department of Electrical Engineering and Computer Science, Institu Montefiore / Bioinformatics

3:30-3:45 pm
Break
Wildrose Foyer, Level 6, South Wing

3:45-4:30 pm
Research Symposium
Wildrose BC, Level 6, South Wing

Ethics, law and society in the study of allergy

Moderator: Timothy Caulfield, AllerGen Investigator & AllerGen Research Management Committee

Ethics: Ethical and legal issues in birth cohort research
Timothy Caulfield, LL.M., AllerGen Investigator
Research Director, Health Law Institute, University of Alberta

Growing up as a research subject: Ethical and legal issues in birth cohort studies involving genetic research
Nola Ries, LL.M., AllerGen Investigator
Adjunct Assistant Professor, University of Victoria

Fetal programming of allergic diseases: The role of prenatal stress perception in murine and human pregnancies
Dr. Petra Aarck
Brain Body Institute, Department of Medicine, McMaster University, Charité - Medical University Berlin, Germany

4:30-5:30 pm
Research Symposium and Panel Discussion
Wildrose BC, Level 6, South Wing

Preserving the future of the specialty: Increasing Canadian capacity in clinical immunology and allergy

Moderators: Dr. Charles Frankish, President of the Canadian Society of Allergy and Clinical Immunology
Dr. Susan Waterman, AllerGen Investigator, and Associate Professor, McMaster University

The U.S. experience in the development of clinical immunology and allergy specialist programmes
Dr. Stephen J. McGeady
Professor, Pediatrics, Thomas Jefferson University, Philadelphia, Pennsylvania

Panel Discussion and Q&A: Lessons for capacity building in Canada and ways AllerGen NCE can facilitate progress

Panelists:

Dr. Don Stark
Clinical Immunologist and Chair, Specialty Committee on Clinical Immunology and Allergy, Royal College of Physicians and Surgeons of Canada

Dr. Wade Watson
Associate Professor, Department of Child Health, and Head, Section of Allergy and Clinical Immunology, Dalhousie University

5:30-7:00 pm
Poster Session and Adjudication
Wildrose BC and Foyer, Level 6, South Wing

7:00 pm
Adjournment Day Two
Research Symposium & Panel Discussion cont'd

Keynote Speaker

New findings, concepts and hypotheses regarding air pollution, asthma and allergy

Bert Brunekreef, PhD
Professor, Environmental Epidemiology
Vrije Universiteit, the Netherlands

Panel Discussion and Q&A: What environmental exposures are most important to quantify and how much can we realistically know?

Moderator: Frances Silverman, PhD, AllerGen Investigator
Director of Research, Gage Occupational and Environmental Health Unit, and Associate Professor, University of Toronto

Panelists (including Drs. Brook, Brauer and Brunekreef):

Dr. Diane Gold
Associate Professor, Harvard Medical School

Dr. Stephanie Loundan
Senior Investigator, National Institute of Environmental Health Sciences

James Scott, PhD, AllerGen Investigator
Assistant Professor, University of Toronto

Dr. Tim Takaro, AllerGen Investigator
Assistant Professor, Simon Fraser University

10:30-11:00 am
Break
Wildrose Foyer, Level 6, South Wing

11:00 am - 12:30 pm
Research Symposium
Wildrose BC, Level 6, South Wing

Birth cohorts in the study of allergy and asthma: Past, present and future

Moderator: Dr. Peter Paré, Programme Leader, Gene-Environment Interactions

Introduction: Growing up with asthma

Dr. Malcolm Sears, Programme Leader, Gene-Environment Interactions
Research Director, Firestone Institute for Respiratory Health
Professor, McMaster University

Collaboration among European birth cohorts in the GA²LEN network of excellence

Dr. Susanne Lai
Assistant Professor, Charité - Medical University Berlin, Germany
Department of Pediatric Pneumology and Immunology, Campus Virchow Klinikum

Health consequences and environmental burden of allergen exposure: Results of the German birth cohort, ILBA

Joachim Heinrich, PhD
Head, Environmental Epidemiology, GSF National Research Center for Environment and Health, Institute for Epidemiology

12:30-2:00 pm
Luncheon and Poster Viewing
Wildrose ABC and Foyer, Level 6, South Wing

2:00-3:30 pm
Research Symposium and Panel Discussion
Wildrose BC, Level 6, South Wing

CHILDB is born: Nature and nurture

Moderator: Dr. Malcolm Sears, Programme Leader, Gene-Environment Interactions

Objective assessment of lung function and inflammation in infants: Is it possible?

Dr. Padmaja Subbarao, AllerGen Investigator
Assistant Professor, Hospital for Sick Children

Gender differences in the presentation of atopy and asthma: Implications for longitudinal birth cohort studies

Dr. Push Mandhate, AllerGen Investigator
Assistant Professor, University of Alberta

3:30-3:45 pm
Break
Wildrose Foyer, Level 6, South Wing

3:45-4:30 pm
Research Symposium
Wildrose BC, Level 6, South Wing

Ethics, law and society in the study of allergy

Moderator: Timothy Caulfield, AllerGen Investigator & AllerGen Research Management Committee

Ethics: Ethical and legal issues in birth cohort research

Timothy Caulfield, ILM, AllerGen Investigator
Research Director, Health Law Institute, University of Alberta

Growing up as a research subject: Ethical and legal issues in birth cohort studies involving genetic research

Nola Ries, ILM, AllerGen Investigator
Adjunct Assistant Professor, University of Victoria

Fetal programming of allergic diseases: The role of prenatal stress perception in murine and human pregnancies

Dr. Petra Ack
Brain Body Institute, Department of Medicine, McMaster University, Charité - Medical University Berlin, Germany

4:30-5:30 pm
Research Symposium and Panel Discussion
Wildrose BC, Level 6, South Wing

Preserving the future of the specialty: Increasing Canadian capacity in clinical immunology and allergy

Moderators: Dr. Charles Franks, President of the Canadian Society of Allergy and Clinical Immunology
Dr. Susan Waterman, AllerGen Investigator, and Associate Professor, McMaster University

The U.S. experience in the development of clinical immunology and allergy specialist programmes

Dr. Stephen J. McGeady
Professor, Pediatrics, Thomas Jefferson University, Philadelphia, Pennsylvania

Panel Discussion and Q&A: Lessons for CHILD

Panelists:

Dr. Don Stark
Clinical Immunologist and Chair, Specialty Committee on Clinical Immunology and Allergy, Royal College of Physicians and Surgeons of Canada

Dr. Wade Watson
Associate Professor, Department of Child Health, and Head, Section of Allergy and Clinical Immunology, Dalhousie University

5:30-7:00 pm
Poster Session and Adjudication
Wildrose BC and Foyer, Level 6, South Wing

7:00 pm
Adjournment Day Two

Innovation from cell to society
Tuesday, February 12

7:30-8:55 am  Breakfast Buffet  Wildrose A, Level 6, South Wing

8:55-9:00 am  Overview of Day’s Program  Dr. Judah Denburg, McMaster University

9:00-10:30 am  Research Symposium  Wildrose BC, Level 6, South Wing

The immunology of allergy and asthma: CanGoFar and Biomarkers
Moderator: Dean Betts, PhD, Programme Leader, Diagnostics and Therapeutics
Professor of Medicine, University of Alberta

Canadian Group on Food and Allergy Research (CanGoFar) overview
Jean Marshall, PhD, AllerGen Investigator
Professor, Dalhousie University

CanGoFar data
Dr. Manel Jordana, AllerGen Investigator
Associate Professor, McMaster University

Non-invasive assessment of atopic diseases: Metabolomic profiling of urine using Nuclear Magnetic Resonance (NMR)
Dr. Darryl Adamko, AllerGen Investigator
Associate Professor, University of Alberta

Regulation of CRTH2, a receptor involved in allergic inflammation
Lisa Cameron, PhD, AllerGen Investigator
Assistant Professor, University of Alberta

10:30-11:00 am  Break  Wildrose Foyer, Level 6, South Wing

11:00 am-12:30 pm  Research Symposium  Wildrose BC, Level 6, South Wing

Health policy issues in allergy, anaphylaxis and asthma
Moderators: Dr. Allan Becker, Programme Leader, Public Health, Ethics, Policy and Society, and Professor, University of Manitoba
Susan Elliott, PhD, Programme Leader, Public Health, Ethics, Policy and Society, and Dean of Social Sciences and Professor, McMaster University

Food labelling and policies for the allergic consumer
Dr. Ann Clarke, AllerGen Investigator
Associate Professor, McGill University Health Centre

Health professionals: Delivering asthma education and support to children with asthma
Miriam Stewart, PhD, AllerGen Investigator
Professor, University of Alberta

Perinatal stress and immigration: Potential impact on allergic disease development in offspring
Dr. Claudia Soares, AllerGen Investigator
Associate Professor, McMaster University

12:30-2:00 pm  Luncheon and Poster Viewing  Wildrose ABC and Foyer, Level 6, South Wing

2:00-3:30 pm  Research Symposium  Wildrose BC, Level 6, South Wing

Clinical Investigator Collaborative
Moderator: Dr. Paul O’Byrne, Programme Leader, Diagnostics and Therapeutics
Chair, Department of Medicine, McMaster University

Ongoing clinical studies
Dr. Louis-Philippe Boulé, AllerGen Investigator
Professor, University of Laval

Completed clinical studies
Gail Gauvreau, PhD, AllerGen Investigator
Assistant Professor, McMaster University

Conference Program

Sunday, February 10

3:30-4:30 pm  Environmental Exposure Workshop: Public Plenary Session  Hawthorne, Level 6, South Wing

The Cup is half full: Strategies for the selective collection, saving and measurement of estimated exposures in birth cohort studies to test current and future central hypotheses on the origins of allergy and asthma
Dr. Diane Gold
Associate Professor, Harvard Medical School, Brigham and Women’s Hospital, Channing Laboratory, Boston, Massachusetts

5:00-6:00 pm  Opening Ceremonies  Wildrose BC, Level 6, South Wing

Welcome and Introductions
Chaviva Holek, PhD
Vice-Chair, Board of Directors, AllerGen NCE Inc.

Messages from Invited Guests
Dr. Rose Goldstein
Vice-President (Research), University of Calgary
Jacques Magnan, PhD
Interim President and CEO, Alberta Heritage Foundation for Medical Research

Dr. Terry Klassen
Director, Maternal, Infant, Child and Youth Research Network, University of Alberta

AllerGen: Back to the future
Dr. Judah Denburg
Scientific Director and CEO, AllerGen NCE Inc.

6:00-7:00 pm  Opening Keynote Speaker  Wildrose BC, Level 6, South Wing

The relevance of allergen specific IgE antibodies to asthma and other allergic diseases
Dr. Thomas Platts-Mills
Professor of Medicine and Head, Division of Allergy and Clinical Immunology
University of Virginia, Charlottesville, Virginia

7:00-8:00 pm  Welcome Reception for all Conference Delegates  Wildrose A, Level 6, South Wing

8:00-11:00 pm  AllerGen Students and New Professionals Network-Hosted Pub Night  Divas, Level 7

Monday, February 11

7:30-9:00 am  Breakfast Buffet  Wildrose A, Level 6, South Wing

8:55-9:00 am  Welcome  Wildrose BC, Level 6, South Wing

9:00-10:30 am  Research Symposium & Panel Discussion  Wildrose BC, Level 6, South Wing

Assessment of environmental exposure related to asthma and allergy
Moderators: Jeffrey Brook, PhD, AllerGen Research Management Committee (RMG) and Senior Scientist, Air Quality Research Division, Environment Canada
Michael Brauer, ScD, AllerGen Investigator, and Professor, School of Environmental Health, University of British Columbia
Conference Information

The registration desk is located outside the Wildrose Ballroom on Level 6, South Wing, of the Rimrock Resort.

The Registration/Information Desk will be staffed at the following times:

- Sunday, February 10: 1:00 pm to 6:00 pm
- Monday, February 11: 7:30 am to 4:00 pm
- Tuesday, February 12: 7:30 am to Noon

Admission to conference events is by CONFERENCE NAME BADGE ONLY. Registrations are non-transferable and sharing of registration is not permitted.

Full registration includes:

- Sunday Welcome Reception; breakfasts, breaks, lunches, Reception and Gala Dinner at the Rimrock;
- All scientific sessions; and
- Conference handouts.

One-day registration includes:

- Scientific sessions on specific day;
- Breakfasts, breaks and lunches; and
- Conference handouts.

Mark your calendars!
Bienvenue dans le cadre enchanteur de Banff (Alberta) et au troisième congrès scientifique annuel d’AllerGen ayant pour thème L’innovation de la cellule à la société.

Au cours des prochains jours, vous traiterez des plus récents progrès scientifiques dans le domaine des allergies et des déficiences immunitaires. C’est également une occasion pour vous de partager votre expérience et d’échanger des idées pour améliorer la qualité de vie des dizaines de milliers de Canadiens qui souffrent de ces affections.

AllerGen a réussi à mobiliser des chercheurs, cliniciens et partenaires de plusieurs disciplines envers un objectif commun : améliorer la santé des Canadiens et la qualité des soins qui leur sont disponibles. Les efforts déployés par votre Réseau pour acquérir le savoir, commercialiser ses découvertes et former la main d’œuvre hautement spécialisée, contribuent à améliorer la santé et le mieux-être des Canadiens.

Les succès d’AllerGen et les incidences de ses travaux de recherche sont des exemples des avantages qui résultent de la concertation des secteurs public, universitaire et commercial. Le gouvernement du Canada soutient activement la recherche scientifique et la technologie maintenant assurera un Canada en meilleure santé, plus fort et plus viable dans l’avenir.

Au nom du gouvernement du Canada, je tiens à vous remercier pour votre travail inlassable à réduire la souffrance causée par les allergies tout en contribuant à placer le Canada au premier rang de l’économie mondiale du savoir. Je vous souhaite un excellent et fructueux congrès.

L’honorable Jim Prentice
Ministre de l’Industrie

Message de l’honorable Jim Prentice, ministre de l’Industrie
Welcome to beautiful Banff, Alberta, and to AllerGen’s third annual scientific conference, Innovation from Cell to Society.

Over the next few days, you will be discussing the latest scientific advances in the field of allergic and immune diseases. This is also a time for you to share your experiences and ideas to improve the quality of life for the tens of thousands of Canadians who suffer from these conditions.

AllerGen has mobilized researchers, clinicians and partners from many sectors, all of whom are focused on a common goal: improving the health of Canadians and the quality of care available to them. Your Network’s efforts to acquire knowledge, commercialize its discoveries and train highly-qualified knowledge workers are enhancing Canada’s health and well-being.

AllerGen’s successes and the impact of its research are examples of the advantages gained when business, academic and public sectors work together. The Government of Canada is committed to allowing such partnerships to flourish. Through our Science and Technology Strategy, we are fostering an environment where ideas and research are given the leverage needed for meaningful, wide-reaching benefits. Indeed, since Budget 2007, this Government has announced well over $200 million in new funding initiatives to expand and enhance the Networks of Centres of Excellence program alone. These and other recent and ongoing initiatives will allow Canada to take better advantage of the enviable research capacity we have built over the years. Investing in science and technology now will lead to a stronger, healthier, more sustainable Canada in the future.

On behalf of the Government of Canada, I thank you for your ongoing dedication to reducing the suffering caused by allergic disease while helping to place Canada at the forefront of the global knowledge economy. I wish you a productive and enjoyable conference.

The Honourable Jim Prentice
Minister of Industry

About AllerGen

AllerGen NCE Inc. is dedicated to improving the quality of life for people suffering from allergic and related immune diseases.

Our Vision
To create an enduring network of allergy and immune disease experts whose discovery and development efforts contribute to reducing the impact of allergic and related immune diseases nationally and globally.

Our Mission
To catalyze and support discovery, development, networking, capacity building, commercialization and knowledge translation that contribute to reducing the morbidity, mortality and socio-economic burden of allergic and related immune diseases.

Our Strategic Goals
1. Catalyze and support innovative research that contributes to the discovery of the causes of, and ways to prevent, control or eliminate allergic and related immune diseases.
2. Create new opportunities for the training of highly qualified entrepreneurial personnel in allergy research, patient care, innovation and the health system, and advance professional and lay knowledge about allergic and related immune diseases.
3. Catalyze and facilitate the development of new research platforms, tools, processes, products and services arising from discoveries, and promote their commercialization, their use and their influence on public policy.
4. Develop and maintain networking and partnership arrangements that enable knowledge and technology exchange and exploitation (KTEE).
5. Provide responsible, cost effective and accountable management, administration and support to all aspects of AllerGen’s activities.

The Heights We Reach Depend on the Depth of Our Roots.

At McMaster, we know complex issues require integrated solutions. Digging deep is second nature to us. Our innovative and multi-disciplinary approach to research has earned us international acclaim. But more than that, it’s helped to save lives and contribute to the nation’s social and economic well-being.

It is indeed fitting that McMaster University is home to AllerGen NCE Inc., a dynamic centre of excellence that shares our philosophy and approach to research.

mcmaster.ca/research

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. Novartis Pharmaceuticals Canada conducts hundreds of clinical trials across the country seeking new treatments for cardiovascular disease, diabetes, cancer, organ transplantation and ophthalmic diseases. In 2006, the Company invested over $69 million in research and development. Novartis Pharmaceuticals Canada Inc. employs approximately 850 people in Canada and its headquarters are located in Dorval, Quebec.

Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd., Dorval, QC H9S 1A9
(514) 631-6775  www.novartis.ca
Proud Platinum Sponsor of the AllerGen NCE Inc.
Third Annual Research Conference.
GlaxoSmithKline

Your Partner in Respiratory Care is pleased to support AllerGen’s third annual conference, Innovation from Cell to Society

GlaxoSmithKline (GSK) is a research-based pharmaceutical company devoted to discovering and developing new and innovative medicines, vaccines and healthcare products for Canadians and people around the world. Our key products target five major disease areas — respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. GSK is also a leader in the important area of vaccines and we are developing new treatments for cancer.

www.gsk.ca

Do more, feel better, live longer
The programme de la conférence vous invite à approfondir votre connaissance de la recherche multidisciplinaire de pointe portant sur l’asthme et les affections allergiques, en plus d’offrir de nombreuses occasions de réseautage professionnel et personnel qui mènent, nous l’espérons, à de nouvelles initiatives de collaboration et de partenariat.

Nous souhaitons que cette conférence servira de source d’inspiration, qu’elle vous encouragera à aller de l’avant avec de nouvelles idées et à établir de nouveaux partenariats scientifiques et communautaires qui amélioreront la qualité de vie des enfants et des adultes souffrant d’asthme et d’affections allergiques et immunologiques.